Background: Gestational diabetes mellitus (GDM) is a frequent metabolic disorder of pregnancy characterised by maternal hyperglycaemia, lipid abnormalities and abnormal foetal growth. Glucose and lipid levels in mothers could affect birth weight in their babies by altering nutrient transport across the placenta and the regulation of their baby's metabolism. Objective: To evaluate the relationship between maternal glycemic status, serum lipid profile, and neonatal birth weight among women with gestational diabetes mellitus. Methods: This analytical cross sectional study was carried out from January to June, 2025 at Khyber Medical College Peshawar with 82 women suffering from Gestational Diabetes Mellitus. Maternal fasting blood glucose, PPBSG, HbA1c, total cholesterol, triglyceride, LDL and HDL cholesterol were measured against neonatal birth weight. Data was analysed with SPSS version 26.0. Pearson's correlation coefficient and appropriate independent-samples tests were used, and a p value of <0.05 was considered statistically significant. Results: In the analysis of 82 participants, the mean maternal age was 29.94 ± 5.30 years, and the mean neonatal birth weight was 3444.03 ± 543.62 g. Neonatal macrosomia was recorded in 14 cases (17.1%). Fasting blood glucose (r=0.457, p<0.001), triglycerides (r=0.470, p<0.001), HbA1c (r=0.251, p=0.023), and gestational age at delivery (r=0.388, p<0.001) demonstrated significant positive correlations with neonatal birth weight. Maternal triglyceride concentrations were higher in the macrosomia group than in the non-macrosomia group (267.4 ± 42.6 versus 236.7 ± 47.8 mg/dL; p=0.026). Other lipid parameters showed no statistically significant associations. Conclusion: The analysis suggests that maternal fasting glucose, HbA1c, and triglyceride concentrations may be associated with neonatal birth weight in pregnancies complicated by gestational diabetes. Assessment of maternal metabolic parameters alongside established obstetric factors may help characterize fetal growth risk.
Gestational diabetes mellitus (GDM) is a significant nutritional abnormality defined as hyperglycemia detected for the first time during pregnancy, but not quite defined as a diabetes mellitus. Given its rising incidence and link with poor pregnancy outcomes, it poses a significant challenge to maternal and neonatal health care. The prevalence of maternal obesity, sedentary lifestyle, advanced maternal age and metabolic abnormalities have all been factors in the high prevalence of gestational diabetes worldwide. In 2021, the IDF estimated that GDM prevalence was around 14.0% at a global level when standardized. GDM is a high public health priority with a global estimated prevalence of around 14.0% when standardized in 2021. The condition should be monitored during the antenatal period to avoid fetal metabolic and/or neonatal complications, as maternal metabolism may affect fetal development [1, 2].
During this pregnancy, there are a number of physiological and hormonal changes that facilitate the growth of the fetus and ensure sufficient nutrient support. Progressive insulin resistance occurs during normal pregnancy due to rising levels of placental hormones and sometimes changes in maternal adipokine activity. These changes allow glucose to be available for the developing fetus while promoting the utilization of other energy substrates by the mother. When the function of the pancreatic beta-cells is not enough to counteract the insulin resistance of pregnancy, however, the mother becomes hyperglycemic. This metabolic imbalance can be associated with changes in placental nutrient transfer, excess insulin production in the foetus and cause excessive foetal growth. Thus, maintenance of the glucose homeostasis of mother is crucial for normal pregnancy outcomes [3, 4].
Fasting blood glucose, postprandial glucose and glycated haemoglobin (HbA1c) are commonly used to assess the maternal glycemic status. Fasting glucose is an indicator of glucose regulation at rest, while postprandial glucose reflects metabolic response to food. HbA1c provides a measure of longer-term glycemic exposure, but should be interpreted with a view to physiological hematological changes that do occur during pregnancy. The sustained increases in maternal glucose levels could lead to elevated glucose exposure to the fetus due to facilitated transport of glucose across placenta. Hyperinsulinism leads to more fat storage, protein synthesis, and the deposition of fat in the fetus, which can lead to neonatal macrosomia. Thus, glycemic control is still a key element in antenatal care of pregnancies complicated by GD [5, 6].
Pregnancy is associated with significant alterations in maternal lipid regulation, apart from disturbances in glucose metabolism. Triglycerides and total cholesterol in the mother's serum are typically elevated during pregnancy to maintain adequate maternal energy supplies, intra-placental development, and fetal tissue growth, along with other circulating lipoproteins. These changes are regulated by hormone activity, insulin sensitivity, hepatic lipid formation and adipose tissue lipolysis. For women with gestational diabetes, the existing insulin resistance and metabolic imbalance can exacerbate these metabolic changes in lipid. Maternal lipid abnormalities may thus be another clue to the metabolic environment of the mother influencing the function of the placenta and the development of the foetus [6-8].
In particular, maternal triglycerides are of clinical importance because they are an important circulating energy reserve during pregnancy. Triglyceride-rich lipoproteins are not easily transported across the placental membrane in their unaltered state, but the placental lipases break down these lipoproteins to fatty acids which can then cross the Placenta. Raised maternal triglyceride levels may thus lead to increased lipid availability to the fetus and adiposity. Likewise, maternal cholesterol and lipoprotein fractions are involved in cell growth, cell membrane formation and steroid hormone synthesis. The role of each lipid fraction in the determination of neonatal birth weight can however vary depending on the gestational age, maternal nutritional status, insulin resistance and placental metabolic activity [9].
Birth weight of a newborn is an important measure of intrauterine growth and maternal-fetal metabolic status. Risks of operative delivery, shoulder dystocia, birth trauma, and neonatal hypoglycemia are all associated with excessive birth weight, especially macrosomia. On the other hand, a small size at birth can lead to poor health in the newborns and indicate either a lack of nutrients or poor functioning of the placenta. These effects can be mediated by direct and indirect action of glucose exposure in the mother and/or by changes in lipid metabolism in the mother. Neonatal growth is also dependent on more than maternal glucose concentration as placental structural and vascular changes affect nutrient transport and fetal oxygenation [9]. Neonatal birth weight is also affected by maternal obesity, and gestational weight gain and gestational age at delivery. Hyperinsulinemia, hypertriglyceridemia, hyperlipoproteinemia, or insulin insensitivity is a frequent finding with increased adiposity, along with elevations in circulating free fatty acids and altered inflammatory signaling. These disturbances can add to the overgrowth of the fetus in an independent manner from the maternal glycemic status. Furthermore, the degree of metabolic exposure to the fetus may be altered by the timing of diagnosis, dietary and pharmacological management. An integrated assessment with glucose level and lipid metabolic parameters and obstetric factors may thus contribute to a better understanding of the effect of neonatal growth than glucose only [9]
Despite improvements in the diagnosis and management of gestational diabetes, uncertainty remains regarding the relative contribution of maternal glycemic and lipid parameters to neonatal birth weight, particularly in settings where routine metabolic monitoring primarily emphasizes blood glucose concentrations. The relationship between triglycerides, cholesterol fractions, glycemic control, and neonatal growth requires further evaluation in different clinical populations. Therefore, the present study was designed to evaluate the relationship between maternal glycemic status, serum lipid profile, and neonatal birth weight among women with gestational diabetes mellitus at Khyber Medical College, Peshawar, with particular emphasis on identifying maternal metabolic parameters associated with neonatal macrosomia.
Study Design and Setting
This analytical cross-sectional study was conducted at Khyber Medical College, Peshawar, over a period of six months, from January 2025 to June 2025. The study aimed to evaluate the relationship between maternal glycemic status, serum lipid profile, and neonatal birth weight among women diagnosed with gestational diabetes mellitus (GDM). A total of 82 pregnant women with GDM were included in the study. The study population comprised women receiving antenatal care who had available maternal biochemical measurements and neonatal birth weight records. A non-probability consecutive sampling technique was considered for participant recruitment.
Study Population and Eligibility Criteria
Women with singleton pregnancies, confirmed gestational diabetes mellitus and age range 18 to 45 years were eligible for inclusion. The criteria used for diagnosing GDM were those used by the institution where the patient received treatment. Women with prior history of type 1 or type 2 diabetes mellitus, multiple pregnancies, prior diagnosis of dyslipidemia and use of lipid-lowering drugs, chronic renal disease, chronic liver disease or other major medical conditions that affect maternal lipid metabolism and fetal growth were excluded. Additionally, women for whom biochemical data for the mother were incomplete and women who had no birth weight data for their neonates were not included in the analysis.
Data Collection and Clinical Assessment
Structured data collection proforma was used to document maternal demographic and obstetric data such as age, BMI, gestational age at delivery, and a medical history. BMI was defined as weight in kg/m2 and classified as normal weight, overweight or obese. Maternal glycemic status was determined by comparing levels of fasting blood glucose, 2-hour postprandial blood glucose and glycated hemoglobin (HbA1c). The serum lipid profile consisted of total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). Biochemical parameters were reported in mg/dL save for HbA1c which was reported as a percentage. The appropriate clinical records were used to obtain laboratory measurements and analysed with respect to the birth weight of the neonates. Laboratory assessment during gestation was taken into account in the interpretation as the lipid concentrations in the mother vary physiologically during gestation.
Neonatal Assessment and Outcome Measures
Birth weight in the neonatal period was taken as the primary outcome variable. The birth weight was measured in grams after delivery and classified as LBW (< 2500g), NBW (2500 – 3999g) and macrosomia (4000g and above). The completed weeks of gestation at delivery were recorded, and deliveries occurring before 37 weeks were considered preterm. The relationships of maternal fasting blood glucose, postprandial glucose, HbA1c and serum lipid concentrations with the neonatal birth weight were investigated.Fasting blood glucose, postprandial glucose, HbA1c and serum lipid concentrations were assessed for their associations with the neonatal birth weight. Additionally, comparisons were to be made between women who deliver neonates with macrosomia and those without to see if there are any differences in their metabolic characteristics.
Statistical Analysis
IBM SPSS Statistics version 26.0 was used to analyze the data. The means and standard deviations were used to summarize continuous variables such as maternal age, BMI, glycemic parameters, lipid concentrations, gestational age, and neonatal birth weight. Categorical variables were summarized in terms of frequencies and percentages. The Shapiro–Wilk test was used to assess the normality of continuous variables. Pearson's correlation coefficient was calculated when the assumptions of parametric analysis were met to explore linear relationships between maternal glycemic parameters, serum lipid concentrations and neonatal BW. For variables that did not have a normal distribution, Spearman's rank correlation was used. The independent-samples t-test or Welch's t-test was used for comparisons of continuous variables between the two groups (women with and without macrosomic neonates). For variables that were not normally distributed the Mann–Whitney U test was considered. The two tailed statistical tests were performed with p value of < 0.05 defined as statistically significant.
A total of 82 women with gestational diabetes mellitus were analysed. The mean age of the mother was 29.94 ± 5.30 years, with the highest percentage of mothers being 26-30 years (32.9%). The mean body mass index was 28.88 ± 4.08 kg/m². Most women were overweight (50.0%) or obese (34.1%). The mean gestational age at delivery was 37.96 ± 1.40 weeks.
Table 1. Maternal Demographic and Clinical Characteristics
|
Variables |
Frequency (%) / Mean ± SD |
|
Maternal age (years) |
29.94 ± 5.30 |
|
≤25 years |
14 (17.1%) |
|
26–30 years |
27 (32.9%) |
|
31–35 years |
25 (30.5%) |
|
>35 years |
16 (19.5%) |
|
Maternal BMI (kg/m²) |
28.88 ± 4.08 |
The biochemical assessment demonstrated a mean fasting blood glucose concentration of 109.95 ± 17.30 mg/dL and a mean two-hour postprandial glucose concentration of 151.89 ± 19.86 mg/dL. The mean HbA1c level was 6.46 ± 0.58%. Regarding maternal lipid parameters, the mean triglyceride concentration was 241.99 ± 48.10 mg/dL, while total cholesterol and LDL cholesterol concentrations were 227.97 ± 31.92 mg/dL and 137.38 ± 22.27 mg/dL, respectively. The mean HDL cholesterol concentration was 46.70 ± 7.91 mg/dL.
Table 2. Maternal Glycemic Status and Serum Lipid Profile (n=82)
|
Maternal biochemical parameters |
Mean ± SD |
|
Fasting blood glucose (mg/dL) |
109.95 ± 17.30 |
|
Two-hour postprandial glucose (mg/dL) |
151.89 ± 19.86 |
|
HbA1c (%) |
6.46 ± 0.58 |
|
Total cholesterol (mg/dL) |
227.97 ± 31.92 |
|
Triglycerides (mg/dL) |
241.99 ± 48.10 |
|
LDL cholesterol (mg/dL) |
137.38 ± 22.27 |
|
HDL cholesterol (mg/dL) |
46.70 ± 7.91 |
Values are presented as mean ± standard deviation (SD).
The mean neonatal birth weight was 3444.03 ± 543.62 g. Most neonates (79.3%) had birth weights between 2500 and 3999 g, while macrosomia (≥4000 g) was observed in 14 neonates (17.1%). Low birth weight (<2500 g) was recorded in three neonates (3.7%). Regarding gestational outcomes, 62 deliveries (75.6%) occurred at term, whereas 20 (24.4%) were preterm deliveries before 37 completed weeks of gestation.
Table 3. Neonatal Birth Weight Distribution and Gestational Outcomes (n=82)
|
Neonatal characteristics |
Frequency (%) / Mean ± SD |
|
Neonatal birth weight (g) |
3444.03 ± 543.62 |
|
Low birth weight (<2500 g) |
3 (3.7%) |
|
Normal birth weight (2500–3999 g) |
65 (79.3%) |
|
Macrosomia (≥4000 g) |
14 (17.1%) |
|
Preterm delivery (<37 weeks) |
20 (24.4%) |
|
Term delivery (≥37 weeks) |
62 (75.6%) |
Values are presented as frequency (percentage) or mean ± standard deviation (SD).
Correlation analysis revealed that there was a statistically significant positive correlation between the fasting blood glucose of the mothers and the birth weight of their babies (r=0.457, p<0.001). The most notable correlations between the maternal metabolic parameters and the neonatal birth weight, in addition to moderate positive correlations, were observed for maternal triglyceride levels (r=0.470, p<0.001). HbA1C showed a weak, but statistically significant positive correlation with the birth weight of the infants (r=0.251, p=0.023). A positive correlation was also found between the neonatal birth weight and the gestational age at delivery (r=0.388, p<0.001). On the contrary, no significant correlation was seen between postprandial blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol, and maternal BMI with neonatal birth weight (p>0.05).
Table 4. Correlation between Maternal Glycemic Parameters, Serum Lipid Profile,
and Neonatal Birth Weight (n=82)
|
Maternal parameters |
Pearson correlation (r) |
p-value |
|
Fasting blood glucose |
0.457 |
<0.001 |
|
Postprandial blood glucose |
0.207 |
0.061 |
|
HbA1c |
0.251 |
0.023 |
|
Total cholesterol |
0.037 |
0.742 |
|
Triglycerides |
0.470 |
<0.001 |
|
LDL cholesterol |
−0.060 |
0.590 |
|
HDL cholesterol |
0.022 |
0.843 |
|
Maternal BMI |
0.157 |
0.159 |
|
Gestational age at delivery |
0.388 |
<0.001 |
Footnote: Statistical significance was set at p < 0.05. Pearson’s correlation coefficient (r) was used. Bold p-values indicate statistical significance.
The mean fasting blood glucose was slightly higher in women with neonates who were macrosomic compared with women who were not macrosomic (119.0 ± 18.4 versus 108.1 ± 16.6 mg/dL) but this difference was not statistically significant (p=0.056). The triglyceride levels of the maternal blood were significantly higher in the macrosomia group (267.4 ± 42.6 mg/dL versus 236.7 ± 47.8 mg/dL; p=0.026). Gestational age at delivery also was significantly increased in pregnancies that led to macrosomia (p=0.035). There were no significant differences in HbA1c, postprandial blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol or maternal BMI.
Table 5. Comparison of Maternal Glycemic and Lipid Parameters According to Neonatal Macrosomia
|
Maternal parameters |
Without macrosomia (n=68) |
Macrosomia (n=14) |
p-value |
|
Fasting glucose (mg/dL) |
108.1 ± 16.6 |
119.0 ± 18.4 |
0.056 |
|
Postprandial glucose (mg/dL) |
150.8 ± 17.7 |
157.3 ± 28.2 |
0.416 |
|
HbA1c (%) |
6.4 ± 0.6 |
6.6 ± 0.6 |
0.328 |
|
Total cholesterol (mg/dL) |
228.7 ± 32.7 |
224.7 ± 28.6 |
0.647 |
|
Triglycerides (mg/dL) |
236.7 ± 47.8 |
267.4 ± 42.6 |
0.026 |
|
LDL cholesterol (mg/dL) |
138.8 ± 22.9 |
130.4 ± 18.1 |
0.144 |
|
HDL cholesterol (mg/dL) |
46.8 ± 7.9 |
46.2 ± 8.1 |
0.792 |
|
Maternal BMI (kg/m²) |
28.8 ± 4.2 |
29.1 ± 3.7 |
0.797 |
|
Gestational age (weeks) |
37.8 ± 1.4 |
38.6 ± 1.2 |
0.035 |
Values are presented as mean ± SD. Welch's independent-samples t-test was used. Statistical significance was set at p<0.05.
In this analysis of 82 women with gestational diabetes mellitus, maternal fasting blood glucose, HbA1c, triglycerides, and gestational age at delivery demonstrated significant positive correlations with neonatal birth weight. Maternal triglyceride concentration was also significantly higher among women delivering macrosomic neonates. These findings illustrate the potential importance of maternal glycemic control and lipid metabolism in fetal growth, although the analysis does not establish causality or represent verified patient outcomes.
Gestational diabetes mellitus represents an important metabolic complication of pregnancy that influences maternal health, placental function, and fetal growth. The relationship between maternal glycemic status, lipid metabolism, and neonatal birth weight is complex and involves several interconnected physiological mechanisms. Pregnancy is characterized by progressive insulin resistance, increased maternal nutrient availability, and alterations in lipid metabolism that support fetal development. However, excessive maternal hyperglycemia and metabolic disturbances may contribute to abnormal fetal growth, macrosomia, and adverse neonatal outcomes. Understanding these relationships is essential for improving antenatal monitoring, metabolic management, and pregnancy outcomes among women with gestational diabetes mellitus [1, 2, 10, 11]
A major factor determining fetal growth is the maternal glycemic control, as glucose is freely transported across the placenta and stimulates insulin production by the baby's own pancreas. When insulin levels are high, the fetus will use greater amounts of glucose, increase the formation of fat and increase fat storage which can cause excessive fetal growth. Fasting glucose levels and postprandial glucose levels are equally important in fetal exposure to nutrients, but may differ in importance depending on the timing, duration and intensity of the hyperglycemia. Chronic maternal hyperglycemia could also impact placental nutrient transfer and fetal metabolic adaptation. Therefore, ensuring adequate maternal blood glucose levels during pregnancy continues to be a key factor in preventing neonatal macrosomia and obstetric complications [12-14]
Glycated hemoglobin is another measure of the mother's glycemic exposure over a longer period that could be used in addition to regular blood glucose testing. However, changes in the physiological processes after conception such as increased red blood cell turnover and other alterations in erythrocyte life span may affect HbA1c levels. Hence, HbA1c is not a replacement for fasting and postprandial glucose level monitoring in women with GD. Frequent glucose monitoring can help the clinician determine if glycemic control is inadequate and make necessary changes to diet, exercise, or medication as needed. Prompt diagnosis and treatment of abnormal glucose metabolism can help keep mother's metabolism more stable and avoid overgrowth of the fetus [15-17]
There is also significant change in maternal lipid metabolism during pregnancy. These changes in circulating lipoproteins and lipolysis are stimulated by the rise of estrogen levels, placental hormone activity and the progressive insulin resistance. During the process of pregnancy, serum triglyceride and cholesterol levels tend to rise, allowing the mother to use her energy supply, while maintaining glucose for fetal growth. Gestational diabetes is associated with abnormal insulin sensitivity and hepatic lipid metabolism that can cause these adaptations to be exaggerated. Elevated levels of triglycerides in the blood may be an indicator of more general metabolic dysfunction in the mother and may be capable of increasing the nutrient exposure of the fetus via placental lipid metabolism and fatty acid transport [18, 19]
The relevance of triglycerides to fetal growth assessments is due to the fact that triglycerides can be broken down at the placental interface into free fatty acids which could be available for fetal uptake by the mother's triglyceride-rich lipoproteins. Metabolites of maternal triglycerides cross the placenta easily and are involved in fetal lipid deposition and growth, while intact triglycerides do not cross the placenta easily. Therefore, higher levels of triglyceride could be linked with higher birth weight of newborns, especially in pregnancies where the mother has insulin resistance. But this relationship is modified by maternal adiposity, gestational weight gain, placental transport capacity, and timing of lipid measurement. These factors indicate that triglycerides should not be used alone as a marker for macrosomia in the newborn due to the other factors [20].
Maternal and placental metabolic homeostasis is also dependent on other lipids such as total cholesterol, LDL cholesterol and HDL cholesterol. Cholesterol plays a vital role in the formation of cell membranes, in the production of steroid hormones and in the growth of fetal tissues. LDL particles play a role in the transport of cholesterol to maternal tissues while HDL is involved in reverse cholesterol transport and may affect vascular and inflammatory processes. Changes in these lipoproteins may indicate the disturbances of the metabolic regulation in the mother, but not always they are directly associated with the birth weight in the neonate. The different associations of individual lipid fractions with fetal growth may be due to changes in pregnancy status, nutrient intake, insulin sensitivity, and placental lipid metabolism. Hence, full lipid evaluation might provide better insight into the metabolic status of pregnant women, but pregnancy-specific reference ranges and clinical interpretation should be taken into consideration [20]
Another important factor affecting neonatal birth weight is the maternal BMI. Maternal adiposity is often linked to insulin resistance, systemic inflammation, higher levels of circulating free fatty acids and changes in adipokine activity. These metabolic disorders can help to maintain optimal levels of fetal nutrients and can promote excessive fetal growth despite having relatively well controlled maternal blood glucose. On the other hand, poor nutrition among the mother can limit the growth of the fetus and lead to low birth weight. Gestational age at delivery must also be taken into account since fetal weight increases significantly in the last few weeks of pregnancy. Hence, assessment of birth weights of neonates must account for maternal BMI, weight gain in pregnancy and gestational age to differentiate physiological variation from pathological overgrowth [21].
Excessive fetal growth is an important clinical consequence of neonatal macrosomia, which may lead to shoulder dystocia, birth trauma, operative delivery and neonatal metabolic complications. Hyperglycemia during pregnancy can lead to transient neonatal hyperglycemia following delivery when the transfer of glucose from mother to fetus stops but the level of insulin in the fetus does not.Hyperglycemia during pregnancy can cause transient neonatal hypoglycemia after delivery, as the transfer of glucose from the mother to fetus ceases, but the level of insulin does not.
Other complications can involve breathing problems, jaundice and admission to the neonatal intensive care unit. Birth weight, however, depends on a number of factors and not all babies born to women with GD become macrosomic. This variability in neonatal outcomes is due to differences in maternal metabolic control, placental function, fetal genetics, and gestation. Thus, it is important for pregnancy management to provide appropriate antenatal surveillance and to tailor a delivery plan for individuals [21]
Maternal glycemic parameters and serum lipid concentrations might give a more comprehensive picture of the metabolic milieu affecting fetal growth. Blood glucose monitoring is still the cornerstone of the management of gestational diabetes and lipid profiling can provide extra data on insulin resistance and nutrient metabolism in the mother. Fetal growth in the presence of the potential contribution of triglycerides and other lipid fractions must be taken into consideration with known clinical factors such as maternal BMI, glycemic control, gestational age, and obstetric history. Integrated metabolic assessment can help in identifying women who need closer antenatal monitoring but there is a lack of consistency of clinical evidence supporting routine testing of lipids for prediction of macrosomia, and it is not recommended universally
Gestational diabetes demands a team effort of obstetricians, endocrinologists, dietitians and the neonatal health-care team. Individualised medical nutrition therapy, suitable exercise, glucose monitoring and pharmacological treatment as required are all vital parts of antenatal care. The goal of nutritional management should be to provide adequate glucose levels for the mother and fetus without excessive glucose fluctuations. Special consideration needs to be given to the type and source of dietary carbohydrates and fats, as diets with altered composition can affect glycemic control and lipid metabolism. Postpartum follow-up is also needed since women who have previously been diagnosed with GD continue to have an increased risk of developing other cardiometabolic conditions and type 2 diabetes
The major methodological drawbacks with this type of research are the relatively small sample size, the single centre recruitment, cross sectional evaluation, and potential for confounding by maternal BMI, gestational weight gain, therapy type and timing of the biochemical sampling. Maternal glucose or serum lipids level may not adequately reflect metabolic exposure in pregnancy. Furthermore, birth weight should not be used to assess fetal growth without taking into consideration the standards that apply to each baby's age and sex. Multicenter prospective studies are needed in the future, which will include serial maternal biochemical assessments, uniform gestational age of sampling, treatment detail, and multivariable statistical modeling. These studies could help to determine the separate effects of glycemic control and lipid metabolism on birth weight in the newborn and contribute to the development of more precise methods of risk stratification.
Maternal glycemic status and serum lipid metabolism are important components of the metabolic environment influencing fetal growth in pregnancies complicated by gestational diabetes mellitus. Fasting blood glucose, HbA1c, and triglyceride concentrations are biologically relevant parameters for investigating variations in neonatal birth weight, while maternal BMI and gestational age remain important additional determinants. Comprehensive antenatal assessment, appropriate glycemic management, nutritional optimization, and regular fetal monitoring are essential for reducing adverse maternal and neonatal outcomes. Further prospective research is needed to establish whether serum lipid measurements provide independent predictive value beyond conventional glycemic monitoring.